MGTX - MeiraGTx Holdings plc Stock Price, Fair Value and News

$6.97+0.27 (+4.03%)

Delayed as of 18 Feb 2025, 10:59 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MGTX Price Action

Last 7 days

-1.6%

Last 30 days

17.3%

Last 90 days

3.4%

Trailing 12 Months

5.7%

MGTX RSI Chart

MGTX Valuation

Market Cap

523.6M

Price/Earnings (Trailing)

-5.94

Price/Sales (Trailing)

37.59

EV/EBITDA

-20.52

Price/Free Cashflow

-5.11

MGTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MGTX Fundamentals

MGTX Revenue

Revenue (TTM)

13.9M

Rev. Growth (Yr)

113.8%

Rev. Growth (Qtr)

3.8K%

MGTX Earnings

Earnings (TTM)

-88.2M

Earnings Growth (Yr)

11.21%

Earnings Growth (Qtr)

19.11%

MGTX Profitability

EBT Margin

-342.45%

Return on Equity

-92.1%

Return on Assets

-29.44%

Free Cashflow Yield

-19.58%

MGTX Investor Care

Shares Dilution (1Y)

22.89%

Diluted EPS (TTM)

-1.22

MGTX Alerts

2 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	11.4M	8.1M	13.9M	0
2023	15.4M	15.0M	14.5M	14.0M
2022	38.7M	44.4M	42.3M	15.9M
2021	15.9M	18.6M	20.4M	37.7M
2020	16.7M	17.2M	18.7M	15.6M
2019	0	0	0	13.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About MeiraGTx Holdings plc

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

CEO	Dr. Alexandria Forbes Ph.D.
WEBSITE	https://meiragtx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	406

MeiraGTx Holdings plc Frequently Asked Questions

What is the ticker symbol for MeiraGTx Holdings plc? What does MGTX stand for in stocks?

MGTX is the stock ticker symbol of MeiraGTx Holdings plc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MeiraGTx Holdings plc (MGTX)?

As of Fri Feb 14 2025, market cap of MeiraGTx Holdings plc is 523.63 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MGTX stock?

You can check MGTX's fair value in chart for subscribers.

Is MeiraGTx Holdings plc a good stock to buy?

The fair value guage provides a quick view whether MGTX is over valued or under valued. Whether MeiraGTx Holdings plc is cheap or expensive depends on the assumptions which impact MeiraGTx Holdings plc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MGTX.

What is MeiraGTx Holdings plc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Feb 14 2025, MGTX's PE ratio (Price to Earnings) is -5.94 and Price to Sales (PS) ratio is 37.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MGTX PE ratio will change depending on the future growth rate expectations of investors.